IDEAS home Printed from https://ideas.repec.org/p/ohe/conrep/001818.html
   My bibliography  Save this paper

Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

Author

Listed:
  • Zamora, B.
  • Maignen, F.
  • O'Neill, P.
  • Mestre-Ferrandiz, J.
  • Garau, M.

Abstract

The European Commission's (EC) Orphan Medicinal Products Regulation intended to incentivise the research, development and marketing of new treatments for rare and chronically disabling or life-threatening diseases. Marketing authorisation granted to orphan medicinal products (OMPs) is however only the first step; patients have access to medicines once reimbursement or health technology assessment (HTA) decisions are implemented by national health systems. Our analysis found that since the implementation of the OMPs Regulation in 2000, 143 OMPs obtained a marketing authorisation in the EU. These OMPs are most widely accessible in Germany and France. In the other countries between 30% and 60% of OMPs are reimbursed. In England, less than 50% of OMPs are routinely funded by the NHS, with one-third of these recommended by NICE. The remaining products are directly procured and made available to patients by NHS England via commissioning policies or through the Cancer Drugs Fund. In Germany reimbursement is automatically granted to all medicines which receive a marketing authorisation, immediately after it. For the other countries, the shortest time from authorisation to a reimbursement decision is observed in France and Italy which takes on average 19 months.

Suggested Citation

  • Zamora, B. & Maignen, F. & O'Neill, P. & Mestre-Ferrandiz, J. & Garau, M., 2017. "Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries," Consulting Reports 001818, Office of Health Economics.
  • Handle: RePEc:ohe:conrep:001818
    as

    Download full text from publisher

    File URL: https://www.ohe.org/system/files/private/publications/Access%20to%20OMPs%20Report.pdf
    Download Restriction: no

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. repec:spr:pharme:v:36:y:2018:i:5:d:10.1007_s40273-018-0632-7 is not listed on IDEAS

    More about this item

    Keywords

    Other;

    JEL classification:

    • I1 - Health, Education, and Welfare - - Health

    NEP fields

    This paper has been announced in the following NEP Reports:

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ohe:conrep:001818. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Publications Manager). General contact details of provider: http://edirc.repec.org/data/ohecouk.html .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.